Compare Citius Pharmaceuticals Inc (CTXR) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while YieldMax NVDA Option Income Strategy ETF trades at $12.57 (market cap $1.45B). The key difference: YieldMax NVDA Option Income Strategy ETF is far larger — about 106.5× Citius Pharmaceuticals Inc's market cap, and YieldMax NVDA Option Income Strategy ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| CTXR | NVDY | |
|---|---|---|
Market Cap | $13.62M | $1.45B |
Volume | 132,438 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $17.21 |
52-Week Low | $0.48 | $11.58 |
Typical Hold Time | 17 Days | 43 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $12.62, down 3.0% today amid bearish technical signals. The ETF generates income through covered calls on NVIDIA stock but faces structural limitations on upside participation. Recent analyst commentary highlights concerns about NAV erosion despite the attractive 39.7% annualized distribution rate. Technical indicators show bearish momentum with support at $12 and resistance at $13.
The outlook remains cautious as declining NVIDIA volatility reduces option income potential. While weekly distributions provide income, the capped upside and NAV erosion present significant risks for long-term investors. Analyst consensus leans toward Hold ratings, suggesting limited growth prospects despite strong underlying NVIDIA fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
